-
2023-504146-60-00
10
2024-02-07
lymphatic malformations associated with PIK3CA mutation
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2022-500495-65-00
5
2023-12-06
Haemophilia
-
2022-502597-16-00
9
2023-10-27
Intermediate or High-risk Primary or Secondary
Myelofibrosis
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2022-500470-33-00
5
2022-11-14
Haemophilia
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2024-512089-32-00
3
2022-03-28
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2023-504152-97-00
5
2021-11-26
Generalized Myasthenia Gravis
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2023-504417-67-00
6
2020-12-22
Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia